← Back to Clinical Trials
Recruiting NCT06537453

NCT06537453 UPTAKE - Virtual Care: Virtual Home Hospital With Remote Monitoring to Reduce Acute Care Hospitalization

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06537453
Status Recruiting
Phase
Sponsor University of Calgary
Condition Acute Kidney Injury
Study Type INTERVENTIONAL
Enrollment 354 participants
Start Date 2024-08-10
Primary Completion 2026-08-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Virtual Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 354 participants in total. It began in 2024-08-10 with a primary completion date of 2026-08-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death Study Intervention: Multi-component Digital Health Solutions, including: 1. Computerized Clinical Decision Support (CDS) and 2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years old. * AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17. * Hospitalization \> 48 hours. * LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher. * Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones. Exclusion Criteria: * Non-Alberta residents. * Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs. * C1 or C2 goals of care. * Hospitalization \> 30 days. * Will be discharged to long-term care. * Kidney failure receiving dialysis. * Already admitted in Virtual Home Hospital Program

Contact & Investigator

Central Contact

Director

✉ cccr@ucalgary.ca

📞 +1 (403) 210. 6730

Principal Investigator

Matthew James, MD

PRINCIPAL INVESTIGATOR

University of Calgary

Frequently Asked Questions

Who can join the NCT06537453 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06537453 currently recruiting?

Yes, NCT06537453 is actively recruiting participants. Contact the research team at cccr@ucalgary.ca for enrollment information.

Where is the NCT06537453 trial being conducted?

This trial is being conducted at Calgary, Canada, Edmonton, Canada.

Who is sponsoring the NCT06537453 clinical trial?

NCT06537453 is sponsored by University of Calgary. The principal investigator is Matthew James, MD at University of Calgary. The trial plans to enroll 354 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology